Genmab A/S (ETR:GE9)

Genmab Statistics

Total Valuation

Genmab has a market cap or net worth of EUR 15.24 billion. The enterprise value is 12.45 billion.

Market Cap	15.24B
Enterprise Value	12.45B

Important Dates

The last earnings date was Thursday, November 6, 2025.

Earnings Date	Nov 6, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	61.57M
Shares Outstanding	n/a
Shares Change (YoY)	-3.12%
Shares Change (QoQ)	+0.13%
Owned by Insiders (%)	1.16%
Owned by Institutions (%)	52.90%
Float	60.85M

Valuation Ratios

The trailing PE ratio is 11.29 and the forward PE ratio is 15.91.

PE Ratio	11.29
Forward PE	15.91
PS Ratio	4.65
PB Ratio	3.11
P/TBV Ratio	4.90
P/FCF Ratio	13.46
P/OCF Ratio	13.06
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 9.80, with an EV/FCF ratio of 11.00.

EV / Earnings	9.23
EV / Sales	3.80
EV / EBITDA	9.80
EV / EBIT	10.30
EV / FCF	11.00

Financial Position

The company has a current ratio of 6.03, with a Debt / Equity ratio of 0.02.

Current Ratio	6.03
Quick Ratio	6.01
Debt / Equity	0.02
Debt / EBITDA	0.10
Debt / FCF	0.11
Interest Coverage	54.85

Financial Efficiency

Return on equity (ROE) is 29.41% and return on invested capital (ROIC) is 16.02%.

Return on Equity (ROE)	29.41%
Return on Assets (ROA)	13.38%
Return on Invested Capital (ROIC)	16.02%
Return on Capital Employed (ROCE)	22.58%
Revenue Per Employee	1.22M
Profits Per Employee	503,327
Employee Count	2,682
Asset Turnover	0.58
Inventory Turnover	17.23

Taxes

In the past 12 months, Genmab has paid 167.36 million in taxes.

Income Tax	167.36M
Effective Tax Rate	11.03%

Stock Price Statistics

The stock price has decreased by -25.68% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-25.68%
50-Day Moving Average	264.46
200-Day Moving Average	n/a
Relative Strength Index (RSI)	38.40
Average Volume (20 Days)	182

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Genmab had revenue of EUR 3.28 billion and earned 1.35 billion in profits. Earnings per share was 21.39.

Revenue	3.28B
Gross Profit	3.09B
Operating Income	1.21B
Pretax Income	1.52B
Net Income	1.35B
EBITDA	1.25B
EBIT	1.21B
Earnings Per Share (EPS)	21.39

Balance Sheet

The company has 2.91 billion in cash and 121.03 million in debt, giving a net cash position of 2.79 billion.

Cash & Cash Equivalents	2.91B
Total Debt	121.03M
Net Cash	2.79B
Net Cash Per Share	n/a
Equity (Book Value)	4.90B
Book Value Per Share	79.61
Working Capital	3.18B

Cash Flow

In the last 12 months, operating cash flow was 1.17 billion and capital expenditures -34.41 million, giving a free cash flow of 1.13 billion.

Operating Cash Flow	1.17B
Capital Expenditures	-34.41M
Free Cash Flow	1.13B
FCF Per Share	n/a

Margins

Gross margin is 94.36%, with operating and profit margins of 36.87% and 41.17%.

Gross Margin	94.36%
Operating Margin	36.87%
Pretax Margin	46.28%
Profit Margin	41.17%
EBITDA Margin	38.12%
EBIT Margin	36.87%
FCF Margin	34.54%

Dividends & Yields

Genmab does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	3.12%
Shareholder Yield	3.12%
Earnings Yield	8.86%
FCF Yield	7.43%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Genmab has an Altman Z-Score of 9.17 and a Piotroski F-Score of 5.

Altman Z-Score	9.17
Piotroski F-Score	5